Codexis, Inc.
CDXSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Codexis, Inc. (CDXS) is listed under Biotechnology. At a $200.0M market cap, Codexis, Inc. ranks as a micro-cap company within healthcare. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route.
Market Cap
$200.0M
Beta
2.50
P/E (TTM)
—
P/E (Fwd)
-5.95
EPS (TTM)
$-0.35
EPS (Fwd)
$-0.37
ROE
-68.9%
ROA
-12.5%
Cash
$65.1M
Total Debt
$72.9M
Free CF
-$8.5M
52W Change
-27.9%
Annual Financials
Cash vs Debt
Where CDXS stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, CDXS finished 8.67% above its 150-day moving average ($1.96) and 5.45% above its 200-day moving average ($2.02). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CDXS overbought or oversold?
At the July 15, 2026 close, CDXS's RSI(14) was 40.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Codexis, Inc. carries $72.9M in total debt against $65.1M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$8.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -68.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $138.6M (2022) to $70.4M (2025), a 49% decline worth watching.
Codexis, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Codexis, Inc.'s trajectory.